Clinical Trial Update: Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluated tiotropium delivered via Respimat vs placebo in children aged 1 to 5 with persistent asthma. The study is completed and results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Spiriva (tiotropium) inhalation via Respimat (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2015-06-23